Contact
Payer
SUPPORT
fnsupport@mmitnetwork.com
267-751-3131
SALES
payersales@mmitnetwork.com
267-751-3161
Pharma
SUPPORT
support@mmitnetwork.com
267-751-3130
SALES
pharmasales@mmitnetwork.com
267-751-3162
Provider
SUPPORT
providersupport@mmitnetwork.com
267-751-3164
SALES
providersales@mmitnetwork.com
267-751-3163
Search this site on Google
Search Google
<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=29220&fmt=gif">
<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=29220&fmt=gif">
Formulary guidance and transparency from P&T to point of care
Payer
Manage
Guide
Publish
Pharma
Analyze
Promote
Assess
Provider
Search
Discover
Decide
MMIT Reality Check on Epilepsy (Jan 2021)
Trends That Matter for MCO's Role in COVID Vaccine Rollout
Radar On Market Access: Centene, UnitedHealth Ring in New Year With M&A
Radar On Market Access: FDA Approves First Oral Treatment for HAE Attack Prevention
MMIT Reality Check on Non-Small Cell Lung Cancer ALK+ or ROS1+ (Jan 2021)
Perspectives on New-to-Market Oral Drugs
Radar On Market Access: Supreme Court's ACA Ruling May Upend Biosimilars Market
Radar On Market Access: Despite New Approvals, Plans Still Favor Generics for Epilepsy
MMIT Reality Check on Metastatic Prostate Cancer (Dec 2020)
Trends That Matter for COVID Vaccine Distribution
Radar On Market Access: Surprise Medical Billing Comes to An End, Insurers Oppose Arbitration Mechanism
Radar On Market Access: PBMs Continue Integration, Face More Regulatory Challenges in 2020
MMIT Reality Check on Migraine Prevention (Dec 2020)
Perspectives on Amazon Pharmacy
Radar On Market Access: MCO Messaging Plays Key Role in COVID Vaccine Rollout
Radar On Market Access: Biden Probably Won't Roll Back New Prior Authorization Proposal
MMIT Reality Check on Breast Cancer HR+/HER2+ (Dec 2020)
Trends That Matter: Centene's ACA Expansion
Radar On Market Access: New-to-Market Oral Drugs May Not Always Have a Leg Up on Injectables
Radar On Market Access: First Round of Vaccines Are Expected to Be Free to the Public
MMIT Reality Check on Nonmetastatic Prostate Cancer (Dec 2020)
Perspectives on Biden Administration's Drug-Pricing Moves
Radar On Market Access: Employers Show Interest in Moving to ICHRAs
Radar On Market Access: Insurers Will Play Key Role in COVID Vaccine Distribution, Reimbursement
MMIT Reality Check on Ovarian Cancer (Dec 2020)
Trends That Matter for Growth Hormone Deficiency Treatments
Radar On Market Access: For PBMs, Amazon Pharmacy May Pose Only Indirect Threat
Radar On Market Access: MA Insurers Report Strong Performance, Predict Enrollment Growth
MMIT Reality Check on Type 2 Diabetes (DPP4 and Combo) (Nov 2020)
Perspectives on CMS Insulin Demo
Radar On Market Access: Teledermatology Program Reduces Patient Wait Time But Doesn't Increase Utilization
Radar On Market Access: Centene Expands ACA Footprint But Faces More Competition
MMIT Reality Check on Multiple Myeloma (Nov 2020)
Trends That Matter for Employer Health Benefits
Radar On Market Access: Insurer-Affiliated PBMs Propel Parent Firms' Revenues in Third Quarter
Radar On Market Access: Biden Administration's Drug-Pricing Moves May Be Limited
MMIT Reality Check on Cystic Fibrosis (Nov 2020)
Perspectives on MA Star Ratings
Radar On Market Access: What's Next for Health Insurers in a Likely Split Congress?
Radar On Market Access: Humana Reports Strong Earnings, But Expects Fourth-Quarter Loss
MMIT Reality Check on Chronic Lymphocytic Leukemia (Nov 2020)
Trends That Matter for Major PBMs' 2021 Formulary
Radar On Market Access: FDA's Approval of Sogroya May Change GH Class Management
Radar On Market Access: Centene Talks ACA's Future, Medicaid Rates in 3Q Earnings Call
MMIT Reality Check on Hepatocellular Carcinoma (Oct 2020)
Perspectives on the Future of ACA
Radar On Market Access: Employers Aim to Narrow Networks, Emphasize COEs, Expand Virtual Care Benefits
Radar On Market Access: Costlier PDPs, Cheaper MA-PDs Participate in CMS Insulin Demo
MMIT Reality Check on Psoriasis (Oct 2020)
Trends That Matter for CAR-T Therapies
Radar On Market Access: Racial Disparities Are Highlighted by Pandemic
Radar On Market Access: Average MA Star Ratings Fall Due to Increased Weights, Cut Points
MMIT Reality Check on Hemophilia A (Factor VIII) (Oct 2020)
Perspectives on Provider Consolidation
Radar On Market Access: Trump's $200 Medicare Drug Card Proposal Prompts Criticism
Radar On Market Access: CVS, OptumRx Exclude Brand-Name Inhalers From 2021 Formularies, Switch Up Diabetes Supplies
MMIT Reality Check on IBS-C (Oct 2020)
Trends That Matter on Trump Administration's Rebate Order
Radar On Market Access: COVID-19 Pandemic May Lower Health Care Costs, But Deferral Impact Exists
Radar On Market Access: If Preexisting Condition Protections Vanish, Health Insurers Probably Won't Cheer
MMIT Reality Check on Merkel Cell Carcinoma (Oct 2020)
Perspectives on Amazon-Sharp HealthCare Deal
Radar On Market Access: New Manufacturing Approach May Drive Down CAR-T Therapies' Prices
Radar On Market Access: Experts Remain Skeptical That SCOTUS Will Scuttle Entire ACA
MMIT Reality Check on Sickle Cell Disease (Sep 2020)
Trends That Matter for COVID Cost-Sharing Waivers
Radar On Market Access: Pandemic, Market Stability Encourage Major Insurers to Expand ACA Footprints
Radar On Market Access: As Payer M&A Slows Down, What's Next?
MMIT Reality Check on Schizophrenia (Sep 2020)
Perspectives on PBM Performance Amid COVID-19
Radar On Market Access: Prime Therapeutics Introduces Real Time Benefit Tool
Radar On Market Access: Trump's International Drug Pricing Order Is Still Missing; Rebate Order Draws Fire
MMIT Reality Check on Acute Migraine (Sep 2020)
Trends That Matter for Large Employers in 2021
Radar On Market Access: Amazon Moves Further Into Health Care Data, Sharp Deal Shows
Radar On Market Access: Some COVID Cost-Sharing Waivers Would Expire Soon
MMIT Reality Check on Breast Cancer HR+/HER2- (Sep 2020)
Perspectives on Telehealth Executive Order
Radar On Market Access: Insurers Expand Flu Vaccination Outreach to Blunt COVID-19 Effects
Radar On Market Access: USPS Delivery Slowdown Is Unlikely to Cause Major Rx Fill Disruption
MMIT Reality Check on Non-Small Cell Lung Cancer Systemic Therapy (Aug 2020)
Trends That Matter for Prostate Cancer Treatments
Radar On Market Access: Payers Face Challenges to Enroll Newly Uninsured
Radar On Market Access: Large Employers Expect Cost Uncertainty, More Virtual Care in 2021
MMIT Reality Check on Ulcerative Colitis (Aug 2020)
Perspectives on UnitedHealth, Humana's Chronic Conditions Programs
Radar On Market Access: COVID-19 Pandemic Amps Up Interest in Home Care
Radar On Market Access: Anthem, Cigna, CVS Report Strong PBM Performance Amid COVID-19
MMIT Reality Check on Duchenne Muscular Dystrophy (Aug 2020)
Trends That Matter for Major Insurers' Performance Amid COVID-19
Radar On Market Access: Trump Administration Issues Telehealth Executive Order, More Acts Are Needed
Radar On Market Access: FDA Approved Two PARP Inhibitors for Prostate Cancer
MMIT Reality Check on Parkinson's Disease (Aug 2020)
Perspectives on Remdesivir's $3,120 Price Tag
Radar On Market Access: Anthem Warns of Greater Commercial Enrollment Drop in Second Half
Radar On Market Access: Experts Are Skeptical of Trump Administration's Drug Pricing Executive Orders
MMIT Reality Check on Kidney Cancer (July 2020)
Trends That Matter for Medicaid MCOs
Radar On Market Access: UnitedHealth, Humana Launch Programs for Chronic Conditions
Radar On Market Access: Manufacturers, Payers Wait on Federal COVID-19 Vaccine Distribution Plan
MMIT Reality Check on Bipolar Disorder (July 2020)
Perspectives on Trump Admin's COVID-19 Testing Payment Guidance
Radar On Market Access: Despite Coronavirus Surge, UnitedHealth Expects Care Utilization to Rebound This Year
Radar On Market Access: Trump Admin's COVID-19 Testing Payment Guidance Stirs Debate
MMIT Reality Check on Psoriatic Arthritis (July 2020)
Trends That Matter for Racial Disparities in MA Plans
Radar On Market Access: IngenioRx Acquires ZipDrug to Improve Medication Adherence, Affordability
Radar On Market Access: Remdesivir's $3,120 Price Tag Stirs Debate
MMIT Reality Check on Acute Lymphoblastic Leukemia (July 2020)
Perspectives on MedImpact’s New Program to Accelerate Pharmacogenomics
Radar On Market Access: Upheld Transparency Rule Is Slated to Reshape Payer-Provider Negotiations
Radar On Market Access: Reports Show Medicaid MCOs Are 'Dominant,' Increase Affordability
MMIT Reality Check on Hemophilia A or B With Inhibitors (July 2020)
Trends That Matter for DMD Therapies
Radar On Market Access: Insurers Are Required to Cover Only 'Medically Necessary' COVID-19 Tests
Radar On Market Access: CMS Proposes New Medicaid Best Price Rules for Pricey Therapies
MMIT Reality Check on Ankylosing Spondylitis (June 2020)
Perspectives on COVID-19 Vaccine Rollout
Radar On Market Access: Telehealth Regulation and Reimbursement Issue Sparks Debates
Radar On Market Access: CMS Report Shows Increasing Racial Disparities in MA Plans
MMIT Reality Check on Urothelial/Bladder Cancer (June 2020)
Trends That Matter: Enrollment Shift Into ACA Exchanges
Radar On Market Access: Pricey Treatments Face Challenges on Cost Sharing and Data Analysis
Radar On Market Access: MedImpact’s New Program Aims to Accelerate Pharmacogenomics
MMIT Reality Check on Endometriosis (June 2020)
Perspectives on ACA Exchanges Amid COVID-19
Radar On Market Access: Uncertainties Over Effectiveness and High Costs Surround DMD Therapies
Radar On Market Access: 2021 MA, Part D Bids Face Challenges Amid COVID-19
MMIT Reality Check on Chronic Idiopathic Constipation (June 2020)
Trends That Matter: The Future of Value-Based Agreements
Radar On Market Access: 1.7K Plans Apply for Trump Admin's Fixed-Insulin-Copay Program for Seniors
Radar On Market Access: Payers and PBMs May Play Key Role in COVID-19 Vaccine Rollout
MMIT Reality Check on Narcolepsy (May 2020)
Perspectives on Surge of Mental Health Meds Use Amid COVID-19
Radar On Market Access: Will COVID-19 Advance Automatic Health Insurance Enrollment?
Radar On Market Access: COVID-19 Pandemic May Change Rx Delivery Permanently
MMIT Reality Check on Low Testosterone (May 2020)
Trends That Matter for Medical-Benefit Drug Spending
Radar On Market Access: COVID-19 Pandemic Drives Home Infusion Utilization
Radar On Market Access: PBMs See Solid 1Q Results Despite Challenges Ahead
MMIT Reality Check on Pain Narcotic Opioid (May 2020)
Perspectives on Coronavirus Antibody Testing
Radar On Market Access: COVID-19 May Drive More Insurers Into ACA Exchanges
Radar On Market Access: CVS Sees COVID Testing Sites as Part of Bigger HealthHUB Strategy
MMIT Reality Check on Anemia — Chronic Kidney Disease (May 2020)
Trends That Matter for Biosimilar Medications Cost Savings
Radar On Market Access: Anthem, Cigna Brace for Recession-Induced Enrollment Shift
Radar On Market Access: Humana, Centene Maintain 2020 Earnings Outlook Amid COVID-19 Pandemic
MMIT Reality Check on Ophthalmic Anti-Inflammatory (Apr 2020)
Perspectives on ACA and Medicaid Enrollment Growth Amid COVID-19
Radar On Market Access: Oncology Drugs Drive Price Growth in Medical-Benefit Spend
Radar On Market Access: PBMs Say Use of Mental Health Meds Surges Amid COVID-19
MMIT Reality Check on Juvenile Idiopathic Arthritis (Apr 2020)
Trends That Matter for Bipolar Disorder Medications
Radar On Market Access: Medicaid MCOs Are Likely to See COVID-Related Enrollment Growth
Radar On Market Access: Insurers Are Now Required to Cover Coronavirus Antibody Testing
MMIT Reality Check on Acute Myeloid Leukemia (Apr 2020)
Perspectives on COVID-19 Outbreak's Impact on Drug Supply
Radar On Market Access: Slow Biosimilar Adoption and Opaque Markets Impede Potential Savings
Radar On Market Access: PBMs Use Dispensing Limits to Halt Hoarding of Trump-Touted Malaria Drugs
MMIT Reality Check on Opioid Dependence (Apr 2020)
Trends That Matter for Cost Impact of Coronavirus Treatment
Radar On Market Access: Amid COVID-19 Outbreak, CMS Relaxes Rules on MA Data Collection
MMIT Reality Check on COPD (Apr 2020)
Perspectives on New Generic HIV Drug
Radar On Market Access: Congress Could Pass Medicare Part D Reform Even Amid COVID-19 Outbreak
MMIT Reality Check on Glaucoma (Mar 2020)
Trends That Matter for Asthma Medications
Radar On Market Access: ACA Plans and Medicaid May See Enrollment Growth Amid COVID-19 Pandemic
Radar On Market Access: Questions Remain About Cost Impact of Coronavirus Treatment
MMIT Reality Check on Major Depressive Disorder (Mar 2020)
Perspectives on Legality of Closed Medicaid Formularies
Radar On Market Access: COVID-19 Outbreak Could Impact Drug Supply Long-Term
Radar On Market Access: Insurers, Pharma Spar Over Copay Accumulator Provision
MMIT Reality Check on Hereditary Angioedema (Mar 2020)
Trends That Matter for Diabetes Drug Costs
Radar On Market Access: Insurers Deploy Array of Strategies to Manage Asthma
Radar On Market Access: Florida Saw Strong MA, Individual Results and More Consolidations
MMIT Reality Check on HIV (Mar 2020)
Perspectives on ACA Exchange Draft Regulation
Radar On Market Access: New Generic HIV Drug May Impact PrEP Coverage, Not HIV Coverage
Radar On Market Access: Tenn. Blues’ White Bagging Policy Sees Pushback from Providers
MMIT Reality Check on Rheumatoid Arthritis (Feb 2020)
Trends That Matter for Nebraska Medicaid Expansion
Radar on Market Access: Future of Medicaid Work Requirements Dims After Arkansas Demo Is Struck Down Again
Radar On Market Access: CVS Touts Aetna’s Contribution; Molina Exchange Business Stumbles
MMIT Reality Check on Type 2 Diabetes (GLP-1 and Combo) (Feb 2020)
Perspectives on Part D Reform in 2020
Radar On Market Access: Payers Try New Strategies to Control Diabetes Drug Costs
Radar On Market Access: Some Experts Question Legality of Closed Medicaid Formularies
MMIT Reality Check on Neutropenia (Feb 2020)
Trends That Matter for Kansas Medicaid Expansion
Radar On Market Access: ACA Exchange Draft Regulation Drops
Radar On Market Access: New Oncology Biosimilar Launches Could Prompt Preferencing
MMIT Reality Check on Multiple Sclerosis (Feb 2020)
Perspectives on Consolidated PBMs in 2020
Radar On Market Access: Sanofi Backs Away From U.S. PCSK9 Market, While Novartis Bets Big With Inclisiran
Radar on Market Access: Nebraska Proposes A Two-Tiered Medicaid Expansion
MMIT Reality Check on Immune Globulin (PID) (Jan 2020)
Radar on Market Access: Disappointing MCOs, Supreme Court Won't Expedite Obamacare Decision
All posts
Learn more about MMIT's solutions
Posts by Topic
Market Access
(557)
Industry Trends
(554)
Payer
(546)
Specialty
(406)
Branding & Marketing
(296)
Provider
(287)
Data & Analytics
(233)
Product Release
(73)
see all
Recent Posts
Subscribe to our blog